{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-303088","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2021-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.110776+00:00","generated_at":"2026-06-28T19:38:32.197182+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Guardant Health appoints Myrtle Potter to Board of Directors","bullets":["Myrtle Potter appointed as Class I director effective Oct 15, 2021; term expires at 2022 Annual Meeting.","Potter also appointed to audit committee; will receive standard non-employee director compensation.","Compensation includes stock option and RSU each valued at $362,500 with modified grant date Nov 8, 2021.","Awards vest 1/4 on first anniversary of appointment, then monthly over three years.","Potter is CEO of Sumitovant Biopharma; previously COO at Genentech and President at Bristol-Myers Squibb."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-303088","json":"https://secwatch.observer/filing/0001193125-21-303088.json","markdown":"https://secwatch.observer/filing/0001193125-21-303088.md","text":"https://secwatch.observer/filing/0001193125-21-303088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000119312521303088/0001193125-21-303088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000119312521303088/d242793d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T19:38:32.197182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3823406724","claim":"Myrtle Potter was appointed as Class I director at Guardant Health, Inc..","evidence_excerpt":"Effective October 15, 2021, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Myrtle Potter as a Class I director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000119312521303088/0001193125-21-303088-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}